Yang Yu, Xu Haineng, Huang Weidan, Ding Miao, Xiao Jing, Yang Dongmei, Li Huaguang, Liu Xin-Yuan, Chu Liang
State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
J Cell Mol Med. 2015 May;19(5):915-23. doi: 10.1111/jcmm.12397. Epub 2015 Feb 16.
Lung cancer stem cell (LCSC) is critical in cancer initiation, progression, drug resistance and relapse. Disadvantages showed in conventional lung cancer therapy probably because of its existence. In this study, lung cancer cell line A549 cells propagated as spheroid bodies (named as A549 sphere cells) in growth factors-defined serum-free medium. A549 sphere cells displayed CSC properties, including chemo-resistance, increased proportion of G0/G1 cells, slower proliferation rate, ability of differentiation and enhanced tumour formation ability in vivo. Oncolytic adenovirus ZD55 carrying EGFP gene, ZD55-EGFP, infected A549 sphere cells and inhibited cell growth. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) armed oncolytic adenovirus, ZD55-TRAIL, exhibited enhanced cytotoxicity and induced A549 sphere cells apoptosis through mitochondrial pathway. Moreover, small molecules embelin, LY294002 and resveratrol improved the cytotoxicity of ZD55-TRAIL. In the A549 sphere cells xenograft models, ZD55-TRAIL significantly inhibited tumour growth and improved survival status of mice. These results suggested that gene armed oncolytic adenovirus is a potential approach for lung cancer therapy through targeting LCSCs.
肺癌干细胞(LCSC)在肿瘤的起始、进展、耐药性及复发过程中起着关键作用。传统肺癌治疗中所呈现出的弊端可能归因于其存在。在本研究中,肺癌细胞系A549细胞在生长因子限定的无血清培养基中形成球体(命名为A549球体细胞)。A549球体细胞表现出癌症干细胞特性,包括化疗耐药性、G0/G1期细胞比例增加、增殖速率减慢、分化能力以及体内肿瘤形成能力增强。携带EGFP基因的溶瘤腺病毒ZD55,即ZD55-EGFP,感染A549球体细胞并抑制细胞生长。携带肿瘤坏死因子相关凋亡诱导配体(TRAIL)的溶瘤腺病毒ZD55-TRAIL表现出增强的细胞毒性,并通过线粒体途径诱导A549球体细胞凋亡。此外,小分子 embelin、LY294002和白藜芦醇提高了ZD55-TRAIL的细胞毒性。在A549球体细胞异种移植模型中,ZD55-TRAIL显著抑制肿瘤生长并改善小鼠的生存状态。这些结果表明,基因武装的溶瘤腺病毒是一种通过靶向肺癌干细胞进行肺癌治疗的潜在方法。